NAVBQ (Navidea Biopharmaceuticals) Long-Term Debt: $0.00 Mil (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAVBQ Navidea Biopharmaceuticals Inc NAVBQ
16 GF Score
Price $0.00
View Full Analysis

What is Navidea Biopharmaceuticals Long-Term Debt?

Navidea Biopharmaceuticals NAVBQ -50.00% 16 Long-Term Debt is $0.00 Mil as of Sep. 2023. GuruFocus rates NAVBQ with a GF Score™ of 16/100.

Navidea Biopharmaceuticals's Long-Term Debt for the quarter that ended in Sep. 2023 was $0.00 Mil.

Navidea Biopharmaceuticals's quarterly Long-Term Debt declined from Mar. 2023 ($1.96 Mil) to Jun. 2023 ($0.00 Mil) but then stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

Navidea Biopharmaceuticals's annual Long-Term Debt stayed the same from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($1.87 Mil).

Navidea Biopharmaceuticals  (OTCPK:NAVBQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Navidea Biopharmaceuticals Long-Term Debt Related Terms

Navidea Biopharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Navidea Biopharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals Long-Term Debt Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.87

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 1.87 1.96 0.00 0.00
NAVBQ
16GF Score
Navidea Biopharmaceuticals Inc NAVBQ
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Navidea Biopharmaceuticals (NAVBQ) has a Long-Term Debt of $0.00 Mil as of Sep. 2023.
Is Navidea Biopharmaceuticals' Long-Term Debt too high?
Navidea Biopharmaceuticals' current Long-Term Debt is $0.00 Mil. Overall, Navidea Biopharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Navidea Biopharmaceuticals' Long-Term Debt compare to PKBO and RSPI?
Navidea Biopharmaceuticals' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Navidea Biopharmaceuticals's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navidea Biopharmaceuticals stock overvalued right now?
Navidea Biopharmaceuticals (NAVBQ) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Navidea Biopharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Navidea Biopharmaceuticals (NAVBQ), the current Long-Term Debt is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navidea Biopharmaceuticals Business Description

Address 4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
16GF Score

Get the complete analysis for NAVBQ

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price